CIMA is a world leader in the drug delivery partnering business, specialising in the formulation, tastemasking and manufacturing of pharmaceuticals using its orally disintegrating tablet (ODT), oral transmucosal, tamper-deterrent, solubilisation and oral powder drug delivery technologies.

ODTs disintegrate in the mouth and can be taken without water. CIMA offers compressed (OraSolv and DuraSolv) and lyophilised (Lyoc) tablets with customised release profile, enteric coating, flavouring and colouring options.

Oravescent, oral transmucosal buccal tablet technology delivers drugs directly through the oral mucosa rather than in the gastrointestinal tract.

Transmucosal drug delivery can result in a greater rate and extent of drug uptake into the systemic circulation, which may also reduce the dose of drug required to produce a therapeutic effect.

OraGuard extended-release/ tamper-deterrent technology provides a robust extended-release PK profile, even during co-administration with alcohol.

It is also resistant against various tampering methods including crushing and ingestion, injection or snorting, chewing, aqueous extraction for IV dosing and alcohol extraction.

Solubilisation (MicroSolv) is a solid self-emulsifying drug delivery system (S-SEDDS) that CIMA developed for insoluble drug candidates. The drug is emulsified and adsorbed onto a powder that can be manufactured as a tablet, capsule or ODT.

Granules/oral powder comprises drug granules packaged in a sachet.

It can accommodate high doses (>1 gram) of drug product. Customised granule size, release profile, enteric coating, flavouring and colouring options are available.

CIMA has proven commercialisation success with more than 20 products marketed in more than 70 countries.

Its expertise includes R&D, formulation, manufacturing and packaging.

The company puts these capabilities to work for its partners to commercialise their products and bring them to doctors and patients around the world.